Category: Gilead Sciences
-
STAT+: New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment
STAT+: New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment ORLANDO, Fla. — With sales of its existing blood cancer CAR-T therapies weakening, Gilead Sciences needs anito-cel, its next CAR-T therapy for multiple myeloma — to succeed more than ever. On Saturday at the annual meeting of the American Society of…
-
STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds
STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds Gilead Sciences, the largest maker of HIV medicines, is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs. And the move is adding to financial uncertainty for the programs on top…